MedTrace Logo

Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy

NCT01255774 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-12-05

No results posted yet for this study

Summary

The rationale for evaluating LucentisTM (a recombinant humanized anti-human Vascular Endothelial Growth Factor (VEGF) monoclonal antibody (Fab) in patients with neovascular (wet) Age related Macular Degeneration (AMD) is based on the strong correlation between VEGF levels in aqueous and vitreous humor and active blood vessel formation. LucentisTM has been shown to maintain or improve vision in wet AMD. Since the treatments do not halt the loss of visual acuity in wet AMD, it is important to accurately measure anatomic response to treatments thereby enhancing the ability to understand patterns of response and predict the necessity for continued therapy.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

ranibizumab

An open-label, study of intravitreally administered ranibizumab

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • The New York Eye & Ear Infirmary

    lead OTHER

Principal Investigators

  • Richard B Rosen, MD · New York Eye and Ear Infirmary

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
51 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01255774 on ClinicalTrials.gov